Natixis Advisors LLC Grows Stock Position in RadNet, Inc. (NASDAQ:RDNT)

Natixis Advisors LLC increased its holdings in RadNet, Inc. (NASDAQ:RDNT) by 11.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 22,530 shares of the medical research company’s stock after acquiring an additional 2,305 shares during the period. Natixis Advisors LLC’s holdings in RadNet were worth $1,563,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RDNT. Covestor Ltd grew its holdings in shares of RadNet by 10,875.0% during the 3rd quarter. Covestor Ltd now owns 439 shares of the medical research company’s stock worth $30,000 after purchasing an additional 435 shares during the period. Nisa Investment Advisors LLC lifted its position in RadNet by 774.2% in the second quarter. Nisa Investment Advisors LLC now owns 848 shares of the medical research company’s stock valued at $50,000 after buying an additional 751 shares during the last quarter. GAMMA Investing LLC boosted its stake in RadNet by 74.7% during the second quarter. GAMMA Investing LLC now owns 865 shares of the medical research company’s stock worth $51,000 after buying an additional 370 shares during the period. Highline Wealth Partners LLC acquired a new stake in shares of RadNet during the third quarter valued at about $68,000. Finally, Profund Advisors LLC purchased a new stake in shares of RadNet in the 2nd quarter valued at approximately $207,000. Institutional investors and hedge funds own 77.90% of the company’s stock.

Analyst Ratings Changes

RDNT has been the subject of several research reports. Barclays upgraded shares of RadNet from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $57.00 to $79.00 in a report on Friday, September 6th. Jefferies Financial Group lifted their price objective on RadNet from $75.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. Truist Financial increased their target price on RadNet from $70.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, Sidoti raised RadNet to a “strong-buy” rating in a research report on Friday, October 4th. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $74.75.

RadNet Trading Down 0.7 %

NASDAQ:RDNT opened at $81.47 on Tuesday. The stock has a fifty day moving average price of $71.01 and a 200 day moving average price of $64.21. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.89. RadNet, Inc. has a 12-month low of $32.01 and a 12-month high of $93.65. The firm has a market cap of $6.03 billion, a PE ratio of -1,192.86 and a beta of 1.75.

Insider Activity at RadNet

In other news, insider Ranjan Jayanathan sold 38,557 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $80.00, for a total value of $3,084,560.00. Following the transaction, the insider now owns 192,724 shares in the company, valued at approximately $15,417,920. This represents a 16.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.12% of the stock is currently owned by corporate insiders.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.